Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Role of GAL3ST1 in the metastasis of renal cell carcinoma

FY 2011-12

Summary
Clear-cell renal cell carcinoma (CCRCC) is the most common type of kidney cancer, and is one of the most aggressive and chemoresistant forms of cancer. The molecular mechanisms regulating CCRCC metastasis - that is, the process by which tumour cells spread and invade distant organs - remain unclear. Most CCRCCs develop as a result of functional mutations in von Hippel-Lindau protein (VHL), a tumour suppressor responsible for the degradation of the transcription factor hypoxia-inducible factor (HIF). As a result, HIF protein levels are often abnormally elevated in CCRCC. In a search for novel genes that may be implicated in CCRCC metastasis, we found remarkably high transcript levels of the GAL3ST1 gene in CCRCC tumours as compared to normal kidney tissue. The protein product of GAL3ST1 is a processing enzyme responsible for the production of a unique cell-surface antigen (sulfatide) that is known to bind adhesion molecules found specifically on platelets and blood vessel walls. The aims of this project are (1) to determine how GAL3ST1 expression is regulated in CCRCC, and (2) to determine the contribution of GAL3ST1 to the metastatic potential of CCRCC. We hypothesize that HIF-driven overexpression of GAL3ST1 increases the levels of sulfatide on the surface of CCRCC cells, thereby facilitating crawling along blood vessel walls and/or providing physical protection in the form of platelet aggregates from cancer-killing cells of the immune system, both of which effectively increase metastatic potential. The results of this project may illuminate innovative therapeutic targets that could be invaluable in the development of more effective therapies for the treatment of metastatic CCRCC.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
247829
Name
Greer Samantha N
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Role of GAL3ST1 in the metastasis of renal cell carcinoma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Flow Cytometry; Gal3st1; Hypoxia; Hypoxia-Inducible Factor; Metastasis; P-Selectin; Renal Cell Carcinoma; Sulfatide; Von Hippel-Lindau Protein
Abstract
Clear-cell renal cell carcinoma (CCRCC) is the most common type of kidney cancer, and is one of the most aggressive and chemoresistant forms of cancer. The molecular mechanisms regulating CCRCC metastasis - that is, the process by which tumour cells spread and invade distant organs - remain unclear. Most CCRCCs develop as a result of functional mutations in von Hippel-Lindau protein (VHL), a tumour suppressor responsible for the degradation of the transcription factor hypoxia-inducible factor (HIF). As a result, HIF protein levels are often abnormally elevated in CCRCC. In a search for novel genes that may be implicated in CCRCC metastasis, we found remarkably high transcript levels of the GAL3ST1 gene in CCRCC tumours as compared to normal kidney tissue. The protein product of GAL3ST1 is a processing enzyme responsible for the production of a unique cell-surface antigen (sulfatide) that is known to bind adhesion molecules found specifically on platelets and blood vessel walls. The aims of this project are (1) to determine how GAL3ST1 expression is regulated in CCRCC, and (2) to determine the contribution of GAL3ST1 to the metastatic potential of CCRCC. We hypothesize that HIF-driven overexpression of GAL3ST1 increases the levels of sulfatide on the surface of CCRCC cells, thereby facilitating crawling along blood vessel walls and/or providing physical protection in the form of platelet aggregates from cancer-killing cells of the immune system, both of which effectively increase metastatic potential. The results of this project may illuminate innovative therapeutic targets that could be invaluable in the development of more effective therapies for the treatment of metastatic CCRCC.
Competitiondate
201111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Greer, Samantha N
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
University of Toronto - $150,000 Grant (2011-12) | Canada Spends